| Literature DB >> 22018790 |
Joshua Roth1, Dmitriy Minond, Etzer Darout, Qin Liu, Janelle Lauer, Peter Hodder, Gregg B Fields, William R Roush.
Abstract
Matrix metalloproteinase-13 (MMP-13) has been implicated as the protease responsible for collagen degradation in cartilage during osteoarthritis (OA). Compounds that inhibit the metalloproteinase at the Zn binding site typically lack specificity among MMP family members. Analogs of the low-micromolar lead MMP-13 inhibitor 4, discovered through high-throughput screening, were synthesized to investigate structure-activity relationships in this inhibitor series. Systematic modifications of 4 led to the discovery of MMP-13 inhibitors 20 and 24 which are more selective than 4 against other MMPs. Compound 20 is also approximately fivefold more potent as an MMP-13 inhibitor than the original HTS-derived lead compound 4. Copyright ÂEntities:
Mesh:
Substances:
Year: 2011 PMID: 22018790 PMCID: PMC3210410 DOI: 10.1016/j.bmcl.2011.09.077
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823